Kathleen Dehaven

Senior Director, Clinical Operations @Edgewise Therapeutics

Boulder, CO, US
EMAILS
k•••••••@edgewisetx.com
MOBILE NUMBERS
+13•••••••40

Signup · Get unlimited contacts

WORK HISTORY

Sep 2025 — Present

Senior Director, Clinical Operations @Edgewise Therapeutics

View department →

Boulder, CO, US

Cardiovascular team. Reporting to SVP, Clinical Research and Operations

EDUCATION

1990 — 1994

University of Pennsylvania

BA, Biological Basis of Behavior

1997 — 1997

George Mason University

Extended Studies, Psychology, Neurology

SKILLS

Clinical OperationsGcpClinical DevelopmentGood Clinical Practice (Gcp)EdcTherapeutic AreasCtmsClinical MonitoringHematologyCrf DesignClinical TrialsPharmaceutical IndustrySopOncologyProtocolCROClinical ResearchBiotechnologyCRO Management

ABOUT KATHLEEN DEHAVEN

Driven, thoughtful and pragmatic clinical trial operations executive with a proven record leading and building out process and teams while fostering a communal, high performing culture. Experienced in global drug development from phase 1 through post marketing, including NDA approval. Passionate about improving access to clinical trials for underserved and under-represented populations and leveraging technology to efficiently execute clinical research. Therapeutic Areas:Cardiovascular - heart failure, hypertrophic cardiomyopathy, pulmonary hypertension, resistant hypertension Oncology – all comer solid tumors, pancreatic, breast, sarcoma, melanoma, prostate, MDS, lymphomaOther - SARS-CoV-2 pneumonia, acute pancreatitis, achromatopsia, Alzheimer’s, anemia, IBD, Chron’s, erosive esophagitis, GERD, hypercholesterolemia, osteoarthritis, alcohol dependence, depression Drug Classes: Cardiovascular - cardiac sarcomere modulators, endothelin receptor antagonists, phosphodiesterase inhibitorsOncology – cell (allogenic TIL & NK, autologous & allogenic vaccine), gene transfer, radiopharmaceutical, targeted (small molecule, monoclonal antibodies), chemotherapyOther - CRAC channel inhibitors, retinal gene therapy, medical food, proton pump inhibitors, Cox-2 inhibitors, SSRIs, opiate antagonistsTrial Designs/Types:p1-4, FIH (patients and healthy volunteer), IIT, EAP, basket, modular, adaptive, emergency/critical care, observational, IDE exempt diagnostic, NSR/SR device, global (Eastern/Western EU, AP, LA)

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.